» Articles » PMID: 22844381

Expression of MiR-21, MiR-31, MiR-96 and MiR-135b is Correlated with the Clinical Parameters of Colorectal Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2012 Jul 31
PMID 22844381
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to determine the expression of miR-21, miR-31, miR-96 and miR-135b in 52 paired colorectal cancer (CRC) tissues and to analyze the correlation between microRNAs (miRNAs) and clinicopathological features. We developed a quantification method that relies on a standard plot, constructed from known concentrations of standards, in order to measure the number of miRNAs. In addition to this, we analyzed the expression levels of miR-21, miR-31, miR-96 and miR-135b in 52 cases of primary CRC and corresponding normal mucosal tissue using real-time PCR with SYBR-Green I. An independent sample t-test was used to compare the differential expression between tumor tissues and normal mucosal tissues. The Mann-Whitney U and Kruskall-Wallis tests were used to compare the correlation between miRNA expression levels and clinicopathological features. The expression of miR-21, miR-31, miR-96 and miR-135b was upregulated in the CRC tissues compared to normal mucosal tissues (P<0.05). Furthermore, miR-21 and miR-135b were positively correlated with the clinical stage (P=0.048 and P=0.029, respectively), while miR-96 and miR-135b were correlated with liver metastasis (P=0.006 and P=0.013, respectively). Our results suggest that miR-21, miR-31, miR-96 and miR-135b may function in the process of CRC development and progression. miR-135b levels in particular may correlate with the degree of malignancy.

Citing Articles

MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.

Ali A, Mahla S, Reza V, Hossein A, Bahareh K, Mohammad H EJHaem. 2024; 5(1):191-205.

PMID: 38406506 PMC: 10887358. DOI: 10.1002/jha2.849.


protects against ischemic stroke by targeting .

Zhan L, Mu Z, Jiang H, Zhang S, Pang Y, Jin H Ann Transl Med. 2023; 11(2):101.

PMID: 36819547 PMC: 9929760. DOI: 10.21037/atm-22-6451.


Non-additive effect of the DNA methylation inhibitor, 5-Aza-dC, and glass as a culture surface on osteogenic differentiation.

Alghfeli L, Parambath D, Tag Eldeen L, El-Serafi I, El-Serafi A Heliyon. 2023; 8(12):e12433.

PMID: 36590514 PMC: 9794900. DOI: 10.1016/j.heliyon.2022.e12433.


A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa.

Mehterov N, Sacconi A, Pulito C, Vladimirov B, Haralanov G, Pazardjikliev D Front Oncol. 2022; 12:1072579.

PMID: 36531016 PMC: 9753689. DOI: 10.3389/fonc.2022.1072579.


A review on the importance of miRNA-135 in human diseases.

Kadkhoda S, Eslami S, Hussen B, Ghafouri-Fard S Front Genet. 2022; 13:973585.

PMID: 36147505 PMC: 9486161. DOI: 10.3389/fgene.2022.973585.


References
1.
Tong A, Fulgham P, Jay C, Chen P, Khalil I, Liu S . MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2008; 16(3):206-16. DOI: 10.1038/cgt.2008.77. View

2.
Schaefer A, Jung M, Mollenkopf H, Wagner I, Stephan C, Jentzmik F . Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2009; 126(5):1166-76. DOI: 10.1002/ijc.24827. View

3.
Aprelikova O, Yu X, Palla J, Wei B, John S, Yi M . The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle. 2010; 9(21):4387-98. PMC: 3055190. DOI: 10.4161/cc.9.21.13674. View

4.
Slack F, Weidhaas J . MicroRNA in cancer prognosis. N Engl J Med. 2008; 359(25):2720-2. PMC: 10035200. DOI: 10.1056/NEJMe0808667. View

5.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M . Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2008; 72(5-6):397-402. DOI: 10.1159/000113489. View